The 15 most recent market catalysts affecting $TWST, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 85
Twist Bioscience shares are trading higher after the company announced an agreement with Lilly TuneLab to advance antibody drug discovery.
This headline represents a significant corporate catalyst for Twist Bioscience. The agreement with a major pharmaceutical company like Eli Lilly (via TuneLab) provides strong valid…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience Announces Agreement With Lilly TuneLab To Advance Antibody Drug Discovery
This collaboration is a significant positive for Twist Bioscience, validating their synthetic biology platform and potentially leading to future revenue streams and partnerships. F…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45
BWS Financial's initiation of coverage on Twist Bioscience with a 'Sell' rating and a $45 price target is a significant event for the company. Analyst ratings, especially new initi…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144
UBS analyst Doug Schenkel initiated coverage on Twist Bioscience (TWST) with a 'Neutral' rating and a $144 price target. This event is significant as it introduces a new institutio…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 85
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
Twist Bioscience (TWST) shares experienced a significant surge, reaching a 52-week high, after Anthropic named them an 'independent evaluator' in an AI-driven protein design campai…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 85
Twist Bioscience shares are trading higher after Anthropic named the company as an independent evaluator in a protein design campaign using its Claude Opus 4.8 and Mythos Preview AI models.
This headline represents a strong corporate catalyst for Twist Bioscience. Being selected by Anthropic, a prominent AI company, as an independent evaluator for a protein design cam…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience shares are trading higher after Piper Sandler maintained its Overweight rating on the stock and raised its price target from $85 to $115.
The headline indicates a significant positive catalyst for Twist Bioscience (TWST). Piper Sandler's maintained 'Overweight' rating and substantial price target increase from $85 to…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 75
Twist Bioscience Announces $250M Public Stock Offering
Twist Bioscience's $250M public stock offering is a significant corporate catalyst. While it provides crucial capital for R&D, manufacturing expansion, and potential M&A, it will l…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115
Baird analyst Catherine Ramsey maintained an 'Outperform' rating on Twist Bioscience and slightly increased the price target from $113 to $115. This action signals continued positi…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 85
Twist Bioscience Sees AI Drug Discovery Pipeline Expand
Twist Bioscience's fiscal Q3 2026 results show a mixed picture with a wider adjusted loss but significantly stronger sales than anticipated, beating both consensus and management g…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 75
Twist Bioscience Corporation shares are trading lower after the company reported mixed Q3 financial results.
The headline indicates a direct corporate catalyst impacting Twist Bioscience. 'Mixed' results often lead to volatility as investors digest both positive and negative aspects, but …
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience Q3 EPS $(0.56) Misses $(0.50) Estimate, Sales $118.376M Beat $114.490M Estimate
The headline indicates a classic 'good news, bad news' scenario for Twist Bioscience. While the sales beat demonstrates strong demand for their synthetic DNA and genomics products,…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience Raises FY2026 Sales Guidance from $442.000M-$447.000M to $456.000M-$457.000M vs $446.103M Est
Twist Bioscience (TWST) has announced an upward revision to its FY2026 sales guidance, moving from $442M-$447M to $456M-$457M. This is a significant development as the new guidance…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 75
Twist Bioscience Sees Q4 Sales $123.000M-$124.000M vs $117.546M Est
Twist Bioscience (TWST) has pre-announced its Q4 sales guidance, projecting figures between $123.000 million and $124.000 million. This range is notably higher than the analyst con…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120
Canaccord Genuity analyst Kyle Mikson has maintained a 'Buy' rating on Twist Bioscience and raised the price target from $90 to $120. This analyst action signals increased confiden…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.